News Related to Biochemical Recurrence

Related coverage linked through entity extraction aliases.

64Cu-SAR-bisPSMA PET/CT Doubles Prostate Cancer Lesion Detection vs 68Ga-PSMA-11 in Phase 2 Trial

May 16, 2026

Phase 2 Co-PSMA trial shows 64Cu-SAR-bisPSMA PET/CT detected 63 prostate cancer lesions vs 24 with 68Ga-PSMA-11, with 78% vs 36% positive scans. Results changed management in 44% of patients.

PSMA-PET Imaging Linked to Earlier Advanced Therapies in Prostate Cancer

May 08, 2026

PSMA-PET imaging leads to earlier use of advanced therapies like ARPIs in prostate cancer patients compared to bone scans. Real-world data on 177Lu-PSMA-617 shows comparable efficacy to the VISION trial in mCRPC patients.